M
Marnix H Geukes Foppen
Researcher at Netherlands Cancer Institute
Publications - 22
Citations - 3917
Marnix H Geukes Foppen is an academic researcher from Netherlands Cancer Institute. The author has contributed to research in topics: Melanoma & Ipilimumab. The author has an hindex of 13, co-authored 18 publications receiving 3012 citations.
Papers
More filters
Journal ArticleDOI
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Eliezer M. Van Allen,Eliezer M. Van Allen,Diana Miao,Diana Miao,Bastian Schilling,Sachet A. Shukla,Sachet A. Shukla,Christian U. Blank,Lisa Zimmer,Antje Sucker,Uwe Hillen,Marnix H Geukes Foppen,Simone M. Goldinger,Jochen Utikal,Jochen Utikal,Jessica C. Hassel,Benjamin Weide,Katharina C. Kaehler,Carmen Loquai,Peter Mohr,Ralf Gutzmer,Reinhard Dummer,Stacey Gabriel,Catherine J. Wu,Catherine J. Wu,Dirk Schadendorf,Levi A. Garraway,Levi A. Garraway +27 more
TL;DR: Investigating the roles of tumor-specific neoantigens and alterations in the tumor microenvironment in the response to ipilimumab found no recurrent neoantigen peptide sequences predicted responder patient populations, suggesting detailed integrated molecular characterization of large patient cohorts may be needed to identify robust determinants of response and resistance to immune checkpoint inhibitors.
Journal ArticleDOI
Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.
Judith Müller,Oscar Krijgsman,Jennifer Tsoi,Lidia Robert,Willy Hugo,Chunying Song,Xiangju Kong,Patricia A. Possik,Paulien Cornelissen-Steijger,Marnix H Geukes Foppen,Kristel Kemper,Colin R. Goding,Ultan McDermott,Christian U. Blank,John B. A. G. Haanen,Thomas G. Graeber,Thomas G. Graeber,Antoni Ribas,Roger S. Lo,Daniel S. Peeper +19 more
TL;DR: It is demonstrated that a low MITF/AXL ratio predicts early resistance to multiple targeted drugs, and warrant clinical validation of AXL inhibitors to combat resistance of BRAF and NRAS mutant MITF-low melanomas.
Journal ArticleDOI
Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab.
Alexander Martens,Kilian Wistuba-Hamprecht,Marnix H Geukes Foppen,Jianda Yuan,Michael A. Postow,Phillip Wong,Emanuela Romano,Amir Khammari,Brigitte Dréno,Mariaelena Capone,Paolo A. Ascierto,Anna Maria Di Giacomo,Michele Maio,Bastian Schilling,Antje Sucker,Dirk Schadendorf,Jessica C. Hassel,Thomas Eigentler,Peter Martus,Jedd D. Wolchok,Christian U. Blank,Graham Pawelec,Claus Garbe,Benjamin Weide +23 more
TL;DR: A baseline signature of low LDH, AMC, and MDSCs as well as high AEC, Tregs, and RLC is associated with favorable outcome following ipilimumab.
Journal ArticleDOI
Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management
Marnix H Geukes Foppen,Elisa A. Rozeman,Sandra van Wilpe,Cindy Postma,Petur Snaebjornsson,Johannes V. Van Thienen,Monique E. van Leerdam,Michel M. van den Heuvel,Christian U. Blank,Jolanda M. van Dieren,John B. A. G. Haanen +10 more
TL;DR: The correlation between grade of diarrhoea and endoscopic or histological features for severity of colitis is poor and endoscopy may have value in the evaluation of the severity of IRC.
Journal ArticleDOI
Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors.
Julia Boshuizen,Louise A. Koopman,Oscar Krijgsman,Aida Shahrabi,Elke Gresnigt-van den Heuvel,Maarten A. Ligtenberg,David W. Vredevoogd,Kristel Kemper,Thomas Kuilman,Ji-Ying Song,Nora Pencheva,Jens Thing Mortensen,Marnix H Geukes Foppen,Elisa A. Rozeman,Christian U. Blank,Maarten L. Janmaat,David Satijn,Esther C.W. Breij,Daniel S. Peeper,Paul W. H. I. Parren,Paul W. H. I. Parren +20 more
TL;DR: These findings provide proof of concept for the premise that rationalized combinatorial targeting of distinct populations in heterogeneous tumors may improve therapeutic effect, and merit clinical validation of AXL-107-MMAE in both treatment-naive and drug-resistant cancers in mono- or combination therapy.